ResultsIQ

ResultsIQ › Latest results › Artemis Medicare Services Limited

Artemis Medicare Services Limited Q1 FY26 results deck summary

NSE: ARTEMISMED · BSE: 542919

Results deck of 6 Aug 2025, summarised by AI from the filing.

Q1 FY26 consolidated gross revenue ₹2,681 cr, EBITDA ₹483 cr, PAT ₹212 cr; third tower opened taking capacity to 700+ beds.

Key takeaways

  1. Revenue Consolidated gross revenue ₹2,681 cr (Q1 FY25: ₹2,344 cr, +14.4%); net revenue ₹2,550 cr (Q1 FY25: ₹2,232 cr, +14.2%).
  2. EBITDA Consolidated EBITDA ₹483 cr (Q1 FY25: ₹406 cr, +19.1%); EBITDA margin 19.0% (Q1 FY25: 18.2%).
  3. PAT Consolidated PAT ₹212 cr (Q1 FY25: ₹165 cr, +28.2%); PAT margin 8.3% (Q1 FY25: 7.4%).
  4. Third tower Third tower opened, taking capacity to 700+ beds; it will be operationalised in a phase-wise manner.

Original filing on BSE

Artemis Medicare Services Limited Q1 FY27 results

As filed: Revenue ₹287 cr (+13% year on year), EBITDA ₹56.5 cr (+38% year on year), PAT ₹31.4 cr (+50% year on year), EBITDA margin 19.7% (+357 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹279 cr (+16% year on year), EBITDA ₹51.6 cr (+39% year on year), PAT ₹30.3 cr (+32% year on year), EBITDA margin 18.5% (+306 bps). Score 67 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was below it. EBITDA margin rose 306 bps year on year. Profit rose ₹7.3 cr on a year ago, against ₹9.0 cr the year before. Share price after the results: +1.0% in 28 days (Nifty 500: −2.8%).
  • Q3 FY26: Revenue ₹272 cr (+17% year on year), EBITDA ₹44.6 cr (+20% year on year), PAT ₹22.2 cr (+22% year on year), EBITDA margin 16.4% (+42 bps). Score 51 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was in line with it; profit before exceptional items growth was well below it. EBITDA margin rose 42 bps year on year. Other income 25% of PBT. Profit fell 16% from last quarter. Profit before exceptional items rose ₹5.8 cr on a year ago, against ₹11.0 cr the year before. Share price after the results: −2.5% in 30 days (Nifty 500: −1.9%).
  • Q2 FY26: Revenue ₹275 cr (+14% year on year), EBITDA ₹50.0 cr (+16% year on year), PAT ₹30.0 cr (+36% year on year), EBITDA margin 18.2% (+34 bps). Score 53 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA and profit growth were below it. EBITDA margin rose 34 bps year on year. Profit rose ₹8.0 cr on a year ago, against ₹8.0 cr the year before. Share price after the results: +9.2% in 30 days (Nifty 500: −0.6%).
  • Q1 FY26: Revenue ₹255 cr (+14% year on year), EBITDA ₹41.0 cr (+11% year on year), PAT ₹21.0 cr (+24% year on year), EBITDA margin 16.1% (−51 bps). Score 44 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin fell 51 bps year on year. Profit fell 9% from last quarter. Profit rose ₹4.0 cr on a year ago, against ₹7.0 cr the year before. Share price after the results: −8.9% in 30 days (Nifty 500: +0.1%).
  • Q4 FY25: Revenue ₹240 cr (+7% year on year), EBITDA ₹37.0 cr (−3% year on year), PAT ₹23.0 cr (+64% year on year), EBITDA margin 15.4% (−147 bps). Score 29 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA growth was well below it; profit growth was above it. EBITDA margin fell 147 bps year on year. Other income 41% of PBT. Profit rose ₹9.0 cr on a year ago, more than the ₹3.0 cr it added the year before. Share price after the results: +3.9% in 30 days (Nifty 500: +3.7%).
  • Q3 FY25: Revenue ₹232 cr (+6% year on year), EBITDA ₹37.0 cr (+16% year on year), PAT ₹21.0 cr (+75% year on year), EBITDA margin 16.0% (+134 bps). Score 36 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA growth was well below it; profit growth was well above it. EBITDA margin rose 134 bps year on year. Other income 33% of PBT. Revenue fell 4% from last quarter. Profit rose ₹9.0 cr on a year ago, more than the ₹2.0 cr it added the year before.
  • Q2 FY25: Revenue ₹241 cr (+7% year on year), EBITDA ₹43.0 cr (+23% year on year), PAT ₹22.0 cr (+57% year on year), EBITDA margin 17.8% (+229 bps). Score 69 of 100, Above trend. EBITDA margin rose 229 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Artemis Medicare Services Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.